Home
    • Plans Blog Contact
    SIGA Technologies Inc logo

    SIGA Technologies Inc

    SIGA
    Last price US$3.00
    Market cap US$215.2m
    12M price change -64.95%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    SIGA Technologies Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for SIGA Technologies Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 06, 2026

    Quarterly result summary

    Revenue was $41M (-49% YoY). Operating income was -$4M (-129% YoY). Net income was $12.5M (-65% YoY).

    Revenue $41M -49% YoY
    Operating income -$4M -129% YoY
    Net income $12.5M -65% YoY

    What changed

    • Revenue -49% YoY to $41M.
    • Operating income -129% YoY to -$4M.
    • Net income -65% YoY to $12.5M.

    Capital return

    Dividend declared at $0.60/share.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 10-Q Aug 06, 2026 SEC filing 8-K Aug 06, 2026 SEC filing FORM 10-Q May 07, 2026 Earnings release EXHIBIT 99.1 May 07, 2026 SEC filing 8-K May 07, 2026 SEC filing 8-K Mar 10, 2026 SEC filing FORM 10-K Mar 10, 2026 Earnings release EXHIBIT 99.1 Mar 10, 2026 SEC filing FORM 10-Q Nov 06, 2025 SEC filing 8-K Nov 06, 2025 Earnings release EXHIBIT 99.1 Nov 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    SIGA Technologies Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 2.63/5
    SIGA Technologies Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    SIGA Technol... SIGA US$215.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.98/5
    SIGA Technologies Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    SIGA Technol... SIGA US$215.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 3.48/5
    SIGA Technologies Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    SIGA Technol... SIGA US$215.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    SIGA Technologies Inc logo

    SIGA Technologies Inc

    US$3.00

    US$215.2m

    -1.64%

    -64.95%